Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 465,264 shares at $0.65 ($298K) on 2021-11-02, disclosed to the SEC on 2021-11-03.
Scheduled sale ($298k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.64 | 454,848 | $291K | 97.7% |
| 2 | $0.65 | 10,416 | $7K | 2.3% |
| Total | $0.64 avg | 465,264 | $298K | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |